Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claim Status
Claims 1-6, 8-10, 13-19, 24, 25, 31, 32 are under examination.
Claims 11, 12, 20-23, 26-30, 33 are canceled.
Priority
Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. It is noted that while a certified copy has been received, the earliest provisional application that provides adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application is provisional application No. 63/326,922. Thus, the priority date of the instant invention is 04/04/2022.
Information Disclosure Statement
The information disclosure statements (IDS) submitted on 01/13/2025, 01/13/2025, and 03/26/2026 have been considered by the examiner.
Drawings
Applicant needs to provide color images of the Figure 1B – Immunofluorescence live imaging of HER2/3-expressing cells in order to view the human receptors HER3 and HER2 co-localize on the cell surface of Dubca cells following lentiviral infection on the merge image.
Applicant needs to provide clear and visible black and white or colored images of Figure 2A- pre immune serum, 2B serum 4th week, 2C Anti-HER3 ab, anti-HER2 Ab in order to clearly identify the signals and bands in the image.
Applicant needs to provide color photographs of the Figure 7 – aHER2-488, Hoechst, NB46-AF647, merge at 1hr and 17hrs images in order to clearly view the staining of the HER receptor and nuclei images.
Immunofluorescence live imaging of HER2/3-expressing cells in order to view the human receptors HER3 and HER2 co-localize on the cell surface of Dubca cells following lentiviral infection on the merge image.
Petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification:
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2).
The drawings are objected to because of the spelling error in Figure 8B on Y-axis, "Vaibility" needs to be corrected to "Viability". Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Abstract
The abstract is objected to due to the words limit of 50 to 150 words. The abstract submitted with the instant application only contains 39 words and does not meet the criteria for abstract submission.
Specification Objections
In the Detailed Description of the Invention section, the term, “bioavailability” needs to be corrected to “Bioviability” in paragraph 30, line 5, pg. 17. “one of skill” needs to be corrected to “One of ordinary skill in the art” in the Detailed Description of the Invention section (paragraph 30, line 6, pg.17). “therebetween” needs to be corrected to “there between” in the Detailed Description of the Invention section (paragraph 25, line 3, pg.18). “8 Nb clones and shows and early stop codon” need to be corrected to “8 Nb clones and shows an early stop codon” (figure 5A-5B, paragraph 4, line 24, pg. 12).
Claim Objections
Claim 1(i) section has a “Sequence No: 3” instead of “SEQ ID NO: 3” and it needs to be corrected (Amendments to the Claims 09/18/2024, Claim 1, pg. 2). Also, the spacing between the SEQ ID NO: 2,3,4 and SEQ ID NO: 6, 7, 8 need to be corrected. Claim 18 recites, “A cell capable of producing an at least one binding molecule” which needs to be corrected to “A cell capable of producing at least one binding molecule” (Amendments to the claims 09/18/2024, Claim 18, pg. 3).
Claim Interpretation
The examiner is reminding applicant that because certain claims narrow the scope of the choice of binding molecules to only binding molecule and fragments, such claims are not listed under rejections that pertain to issues dealing with derivatives and analogs (i.e. claims 10, 13, etc.) and is construed as excluding derivatives and analogs thereof. In the event applicant intends to encompass derivatives and analogs in such claims, appropriate correction is required.
Claim Rejections - 35 USC § 112(a) Written Description
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 2, 3-6, 8-10, 17-19 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a Written Description rejection. Claim 1 recites, “an anti-HER2 binding molecule or a fragment, derivative or analog” with regards to the binding molecules to HER2 protein expressed in breast cancer. Claim 1 lacks a written description for derivatives and analogs of an anti-HER2 binding molecule. The specification provides details on defining the term “binding molecule variant” referring to any molecule comprising the binding molecule of the present invention. For example, fusion proteins in which the binding molecule or an antigen binding fragment is linked to another chemical entity is considered a variant. The specification further includes analogs and variants with conservative and non-conservative substitution, insertion and deletion of amino acids within the sequences of the analogs and variants (Detailed description, paragraph 20, line 2). Additionally, the mutated or modified variants or analogs of the binding molecules are also included within the scope of the invention as long as they confer or improve the binding to the HER2 antigen (paragraph 20, line 1-5, pg. 17). Including such variation would encompass a very large no. of species of binding molecules of which the specification does not provide enough support or written description for one skilled in the art to believe that the applicant was in possession of the claimed invention at the time the invention was made. Therefore, claim 1 is rejected under U.S.C. 35 112(a) written description.
Claim 2 recites, “comprising an amino acid sequence at least about 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 1 and 5”. Claim 2 further introduces 10% variability in the single chain antibody VHH region in the SEQ ID Nos: 1 and 5 with the addition of conservative and non-conservative substitution, insertion, and deletion mutations would further encompass a very large no. of species introducing unpredictability to clearly define the meets and bounds of the claim.
Nanobodies/VHHs bind antigen with only three CDRs. Yau (Journal of Immunological Methods, Vol. 297, Pg. 213-224, 2005) teaches this on page 214, Column 1, Paragraph, first. All three are important for antigen binding as demonstrated by the randomization of all three CDRs in the work of Yau (Figure 1). Importantly, the work of Yau also demonstrates the unpredictability of nanobody CDR mutation and the ability of identifying a functional nanobody with only one CDR defined.
In addition, all three parental CDRs in a camelid antibody/VHH/nanobody participate and are important for antigen binding. Their mutation leads to unpredictable results. This loss of antigen binding via parental CDR mutation is also known for conventional antibodies. Even minor changes in the amino acid sequences of the heavy and light variable regions, particularly in the CDRs, may dramatically affect antigen-binding function as evidenced by Rudikoff et al. (Proc Natl Acad Sci USA 79: 1979-1983, 1982). Rudikoff et al. teach that the alteration of a single amino acid in the CDR of a phosphocholine-binding myeloma protein resulted in the loss of antigen-binding function. Therefore, claim 2 is rejected under U.S.C. 35 112(a) written description.
Similarly, claims 17, 18, and 19 recite, “A polynucleotide encoding the binding molecule according to claim 1”, “A cell capable of producing at least one binding molecule according to claim 1”, “A pharmaceutical composition comprising at least one binding molecule according to claim 1” respectively. However, the specification does not provide any examples or sufficient description with respect to the anti-HER2 binding molecule-VHH nanobodies, derivatives, analogs, or fragments of such binding molecules in regard to the polynucleotide, a cell, or a pharmaceutical composition containing said binding molecule. Therefore, claims 17-19 are also rejected under 35 U.S.C. 112(a) written description rejection.
Thus, claims 3-6, 8-10, 13-19 are rejected under 35 U.S.C. 112(a) as they are either directly or indirectly dependent on Claim 1 and do not provide written description for the anti-HER2 binding molecule and derivatives or analogs of such binding molecule.
Vas-Gath, Inc. v" Mahurkar, 19 USPQ2d 1111, makes clear that "to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed".
The instant application specification neither provides specific/sufficient descriptive information in the structural definition of derivatives and analogs nor is it clear on the function as recited in the claims. Thus, one skilled in the art would reasonably conclude that the inventors, at the time the application was filed, did not have possession of the claimed invention.
Thus, claims 1, 2, 3-6, 8-10, 17-19 are rejected under 35 U.S.C. 112(a) written description rejection.
Claim Rejections - 35 USC § 112(a) Enablement
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 10 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for while being enabling for an anti-HER2 binding molecule such as a nanobody VHH termed as NB46 or NB38 administered in order to treat cancer, does not reasonably provide enablement for a fusion protein comprising the anti-HER2 binding molecule and a tag. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. The specification does not enable the fusion protein comprising the anti-HER2 binding molecule and a tag, because while the specification does provide several examples of such fused proteins such as HA-tagged, His-tagged antibody, affinity, streptavidin, and radiolabeled antibody, it does not provide an example or experimentation of how to make these type of fused proteins -a binding molecule fused to a tag such as HA tagged, His tagged, or streptavidin tagged antibody- and also does not provide sufficient examples on how to use these fused proteins.
Claims 13-16 are also rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a conjugate comprising the anti-HER2 binding molecule attached to a microtubule inhibitor DM1(for example, the NB46-DM1-SMCC antibody drug conjugate) does not reasonably provide enablement for other classes of anti-HER2 binding molecule - VHH nanobodies such as NB38, NB23, etc. or other derivatives, analogs, or fragments of such binding molecule. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. The specification does not enable the conjugate protein comprising the anti-HER2 binding molecule attached to a toxin because it does not provide examples of conjugate -toxin linkage such as NB46-DM1-SMCC with respect to any other VHH nanobodies, or other HER2 nanobody derivatives or analogs to prepare or make and use such antibody drug conjugates to treat HER2+ cancer.
Claims 24, 25, 31, 32 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating, diagnosing, and quantifying HER2+ cancer for a binding molecule such as VHH nanobody NB46, does not reasonably provide enablement for treating said cancer with the derivatives, analogs, and fragments of anti HER2 binding molecule VHH nanobody. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. The specification does not provide enablement for the use of derivatives, analogs, fragments of anti-HER2 binding molecule such as VHH nanobodies. Although the specification does provide examples of treating, diagnosing, quantifying HER2+ expressing cancer using a VHH nanobody NB46, however, the specification does not provide enablement for making derivatives, analogs or fragments of VHH nanobody and also does not provide examples or experimentation of using such derivatives, analogs, and fragments to treat, diagnose, or quantify HER2+ cancer.
To be enabling, the specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1561 (Fed. Cir.,1993). Explaining what is meant by "undue experimentation," the Federal Circuit has stated that:
The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. PPG v. Guardian, 75 F.3d 1558, 1564 (Fed. Cir. 1996).
The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth by In re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 wherein, citing Ex parte Forman, 230 USPQ 546 (Bd. Apls. 1986) at 547, the court recited eight factors to consider when assessing whether or not a disclosure would require undue experimentation. They include the nature of the invention, the state of the prior art, the relative skill of those in the art, the amount of direction or guidance disclosed in the specification, the presence or absence of working examples, the predictability or unpredictability of the art, the breadth of the claims, and the quantity of experimentation which would be required in order to practice the invention as claimed.
These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. In re Fisher, 57 CCPA 1099, 1108,427 F.2d 833, 839, 166 USPQ 18, 24 (1970). Keeping that in mind, the Wands factors are relevant to the instant fact situation for the following reasons:
The Nature of the Invention:
Claim 10 is drawn to a fusion protein comprising an anti-HER2 binding molecule such as VHH nanobody NB46 and a tag. The specification defines fusion protein where the binding molecule or an antigen-binding fragment is linked to another chemical entity considered a variant and this species is referred to as binding molecule variant (paragraph 15-20, line 2, pg. 17).
Claim 13-16 are generally drawn to a conjugate comprising the anti-HER2 binding molecule attached to a toxin selected from the group consisting of microtubule inhibitor, DNA synthesis inhibitor, topoisomerase inhibitor, and RNA polymerase inhibitor. Claim 16 specifically denotes that the microtubule inhibitor is DM1.
Claims 24 and 25 are generally drawn to a method of treating cancer comprising administering to a subject a therapeutically effective amount of at least one binding molecule where the cancer is HER2+ cancer.
Claims 31 is generally drawn to a method of diagnosing or prognosing HER2+ cancer in a subject wherein the method is comprising determining the expression level of HER2 in a biological sample of subject using at least one binding molecule or fragment.
Claim 32 is generally drawn to a method of determining or quantifying the expression of HER2 wherein the method is comprising contacting a biological sample with a binding molecule or fragment.
Breadth of the Claims
Claim 10 is drawn to a fusion protein comprising an anti-HER2 binding molecule and a tag. The fusion proteins as claimed in Claim 10, covers labeling tags, affinity tags, radioactive tags, etc. as listed in specification (Summary of the Invention, paragraph 3, line 5). However, the specification only provides an example of HA-tag or a His tag comprising an amino acid sequence of SEQ ID NO: 9 (paragraph 9, line 25, pg. 7). The specification does not provide examples of other fusion proteins of the anti-HER2 binding molecule attached to other affinity tags such as streptavidin, radio label tags as claimed (Claim 10, pg. 2). Thus, the breadth of the claim is beyond what is enabled in the specification to make and use such fused proteins.
Claims 13-16 are generally drawn to a conjugate comprising the anti-HER2 binding molecule attached to a toxin selected from the group consisting of microtubule inhibitor, DNA synthesis inhibitor, topoisomerase inhibitor, and RNA polymerase inhibitor (spec. pg. 7, lines 11-14). Claim 16 specifically denotes that the microtubule inhibitor is DM1(Claims, pg. 3). The specification defines the term conjugate as comprising a binding molecule and a cytotoxic moiety. The specification also denotes an embodiment where the binding molecule is conjugated to a toxin (Detailed Description of the Invention, paragraph 2, pg. 20). However, the specification only recites an examples of the toxin microtubule inhibitor DM1 attached to the anti-HER2 binding molecule NB46 via SMCC linkage making NB46 DM1-SMCC drug conjugate (Example 5, pg. 38, line 2). The specification does not provide the wide range of derivatives and analogs resulting from substitution mutations in the CDR regions in full detail or even provide a representative set of examples. Similarly, the specification provides example of DM1 conjugated to NB46 but does not provide such examples of other toxins indicated in claim 15. Thus, the breadth of the claim is beyond what is enabled in the specification for claims 13-16.
Claims 24 and 25 are generally drawn to a method of treating cancer comprising administering to a subject a therapeutically effective amount of at least one binding molecule where the cancer is HER2+ cancer. The specification describes the NB46 binding of HER2+ cancer cells and NB46 binding and internalization into HER2+ cancer cells by live imaging assays (paragraph 1, 2, pg. 32). However, the specification does not describe other binding molecule conjugates, derivatives, or analogs or representative examples of each in any detail. Thus, the breadth of the claims are beyond what is enabled in the specification for claims 24 and 25.
Claims 31 is generally drawn to a method of diagnosing HER2+ cancer wherein the method comprising contacting a biological sample with a binding molecule or fragment. The specification shows the immune monitoring using diagnostic assays such as western blot, SDS page electrophoresis by testing the serum sample from the immunized camels with anti-camel-VHH-HRP ab or with mouse anti-human HER2 ab followed by secondary HRP-anti-mouse IgG (paragraph 2, line 13, pg. 27). Other assays such as selection of high affinity Nb binders by colony selection on LB ampicillin plates (paragraph 2, line 23, pg. 28), recombinant expression and purification of nanobodies by using pMECS plasmids guided transformation of E.coli cells (paragraph 2, line 1, pg. 30), SPR binding assays where the affinity of Nbs to HER2/HER3 was determined by SPR spectroscopy (paragraph 2, line 2, pg. 30), etc. were employed for diagnostic purposes with regard to only NB46 nanobody internalization and HER2+ expression in cells. However, these assays do not fully describe other derivatives, analogs of the anti HER2 binding molecule VHH nanobodies with respect to HER2+ expression. Thus, the breadth of the claim is beyond what is enabled in the specification as the full breadth of the VHH nanobodies including the associated derivatives and analogs are not exemplified in the specification as claimed.
Claim 32 is generally drawn to a method of quantifying HER2+ cancer wherein the method is comprising contacting a biological sample with a binding molecule or fragment. The specification describes quantifying assays such as binding analysis of nanobodies against HER2/3 expressing cells where titration analysis of SkBr3, HER2+ breast cancer cells with only Nb46, reveals that Nb46 binds with a high affinity of KD = 0.8nM (Example 2, paragraph 3, pg. 36). The specification also shows binding analysis of NB46 against recombinant HER2 by SPR where the binding affinity of purified NB46 to recombinant HER2 is of sub nanomolar magnitude (Example 3, paragraph 2, line 10, pg. 37). The dissociation constants of KD = 0.24 ± 0.07 nM and KD = 0.17 ± 0.09 nM (average: 0.21 ± 0.08 nM) were measured when the HER receptor was immobilized and the Nb was pumped as the analyte and vice versa, respectively (Figure 8, example 3, paragraph 2, line 10, pg. 37). The specification describes such assays in terms of the NB46 nanobody with regards to HER2+ expression only and does not fully describe other derivatives, analogs of the binding molecule. Thus, the breadth of the claim is beyond what is enabled in the specification as the full breadth of the VHH nanobodies including the associated derivatives and analogs are not exemplified in the specification as claimed.
State of the Art/ the level of predictability in the art:
The administration of trastuzumab and pertuzumab anti-HER2 antibodies is currently well known in the art as current treatments against HER2+ cancer, however, they are suspected to contribute to drug resistance and also reduce HER2 recycling. Due to these reasons currently there is need for more specific, stable and safer methods for treatment of HER2+ cancers. There is also a need for advancing in alternative HER2 binding targets with a different mechanism of action than existing therapy.
Altunay et al. (European Journal of Nuclear Medicine and Molecular Imaging (2021) 48:1371-1389) show HER2 directed antibodies, affibodies, and nanobodies as drug delivery vehicles in HER2 expressing breast cancer. However, the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake and with limited tumor penetration potential (Altunay 2021, abstract). Although, the use of antibody fragments, such as nanobodies, radiolabeled with short-lived radioisotopes, allowing early diagnosis of cancer have shown promising results (Altunay 2021, conclusion, pg. 1383) , however, the attempts to use nanobodies as vehicles for delivering treatment drugs are still ongoing and have not reached measurable success in terms of treating HER2+ cancers and this adds to the level of unpredictability in terms of using nanobodies as targeted drug therapy for HER2+ cancer treatment(Altunay 2021, conclusion, pg. 1384).
Yan et al. (Front. Oncol., 12 May 2021, Vol 21, Article 669393) have also shown a novel HER2 nanobody that inhibits tumor proliferation in HER2+ breast cancer cells in vitro and in vivo. Yan et al. propose and exemplify a direct tumor suppressive role of HER2 nanobody to treat HER2+ breast cancer in vivo and in vitro, reciting its potential use, however, since previously reported HER2 nanobodies could not suppress HER2+ tumor cells directly (Yan 2021, Discussion, pg. 10), the results carry a level of unpredictability in terms of using HER2 nanobodies as alternative route of treatments against HER2+ cancer.
Regarding derivatives and analogs of HER2 nanobody, as recited by Yau et al. (Journal of Immunological Methods, Vol. 297, Pg. 213-224, 2005) can be created via mutations in the CDR region. Such conservative or non-conservative substitution mutations in CDR region will give rise to a large number of HER2 nanobody variants, derivatives, and analogs which will need to be tested in terms of effectively treating HER+ cancer and tumor cells. Hansen et al. propose a HER2 specific nanobody drug conjugate: site selective bioconjugation and in vitro evaluation in breast cancer models (Molecules 2025, 30(2), 391). Hanson et al. show, a method for using in imaging or as an assay reagent, one such variant of a human HER2 specific nanobody, allowing site selective bioconjugation- installation of a drug conjugate (monomethyl auristatin E-functionalized cathepsin B) which demonstrated high potency and selectivity for HER2+ breast cancer models (Hansen 2025, conclusion, pg. 9). However, Hansen et al. also show a level of unpredictability in this method in terms of site-selective biconjugation of HER2 nanobodies compromised when there are higher number of lys residues present in the protein (Hansen 2025, conclusion, pg. 10), further increasing the level of unpredictability for the data obtained by such methods using HER2 nanobody variants.
Thus, the present level of art teaches that HER2 nanobody have currently shown certain level of promising results yet with still high level of unpredictability in terms of using HER2 nanobody as potentially successful method of treatment against HER2+ cancer. Thus existing evidences indicate that there is still level of unpredictability in terms of finding more effective, more specific, and stable form of anti-tumor antibody drug conjugates or nanobody treatments for diagnostic as well as therapeutic purposes.
The amount of direction provided by the inventor/the existence of working examples:
The specification provides an example of NB46 conjugated with SMCC-DM1 (Example 5, pg.38). DM1-SMCC (1072.6 Da) is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody drug conjugate (ADC) (Example 5, pg. 38, line 2) and their concentration analyzed by Nanodrop spectrophotometer, BCA protein assay kit, and MALDI-TOF MS (Figure 12A, figure 12B, pg. 16, 17). However, the specification does not indicate the process of making the NB46 with SMCC-DM1 or provide any working examples of such. Also, the specification does not provide any examples for making other antibodies conjugated to other cytotoxic moieties or those listed in claim 15. Regarding the fusion protein listed in claim 10, the specification does not provide examples of how to make the derivatives or analogs of binding molecules fused to HA-tag or a His tag fusion protein, affinity tags, labeling tags, radioactive tags or examples of such.
The specification only shows in Figure 5A-5B (paragraph 4, line 25, pg. 12) the amino acid sequences and purification of selected nanobodies in terms of NB46 nanobodies. The specification does not show examples of other classes of nanobodies such as NB23, NB38 etc. Also, the specification does not show the conservative or non-conservative mutations created in the CDR region, the amount of species generated as a result, and the amount of species encompassed by each representative class Nb23, NB46, and NB38. Further, the specification does not show if the experiments exemplified in the specification section with regard to NB46 nanobody is representative of all the other classes of nanobodies and accounting for all the mutations in the various CDR regions.
The specification shows the diagnostic assays such as immune monitoring using western blot, SDS page electrophoresis by testing the serum sample from the immunized camels (paragraph 2, line 13, pg. 27) and other quantitative assays such as binding analysis of nanobodies against HER2/3 expressing cells where titration of analysis of SkBr3, HER2+ breast cancer cells with Nb46, reveals that Nb46 binds with a high affinity of KD = 0.8nM (Example 2, paragraph 3, pg. 36). However, the specification only describes such assays in terms of the NB46 nanobody with regards to HER2+ expression and does not fully describe other derivatives, analogs of the anti-HER2 binding molecule or other classes of nanobodies or representative examples of such.
Thus, the examples provided by the specification does not cover all the anti-HER2 binding molecules, derivatives, and analogs claimed in Claim 1 and subsequent dependent claims. Further, since the derivatives and analogs of anti-HER2 binding molecule would encompass a large number of variants, undue experimentation would be required to fully enable the scope of the claimed invention.
The quantity of experimentation needed:
The factors outlined in In Re Wands' mentioned above apply here, and in particular as per the MPEP 2164.01 (a): "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." It is very clear that one could not make/use this very broad invention that has no working examples in this unpredictable art without undue experimentation. Genetech Inc vs Nova Nordisk 42 USPQ 2d 1001 "A patent is not a hunting license. It is not a reward for search but compensation for its successful conclusion and patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable.”
The specification and prior art provide insufficient guidance with regard to these issues and provides insufficient working examples which would provide guidance to one skilled in the art on how to make and use the instant invention. However, no evidence has been provided which would allow one of skill in the art to predict that the invention will function as contemplated or claimed with a reasonable expectation of success. For the above reasons, it appears that undue experimentation would be required to practice the claimed invention in its full scope.
Due to the large and unreasonable quantity of experimentation necessary to test the large number of derivatives, analogs, fusion proteins or fragments claimed with respect to anti-HER2 binding molecule or a VHH nanobody binding to HER2 antigen; the lack of direction/guidance presented in the specification and prior arts; the state of the prior art which establishes the unpredictability in CDR antigen specificity due to mutations, undue experimentation or unreasonable trial and error would be required for the skilled artisan to use the claimed invention in its full scope.
Therefore, claims 10, 13-16, 24, 25, 31, 32 are rejected under 35 U.S.C. 112 (a) Scope of enablement rejection.
Claim Rejections - 35 USC § 112(d)
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection ©, a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 6 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Claim 6 recites the binding molecule comprising an antigen binding domain which is a redundant matter as it is well understood in the art that a VHH which binds Her-2 is expected to have an antigen binding domain. Therefore, claim 6 does not further limit the subject matter recited in Claim 1. Hence, claim 6 is rejected under 35 U.S.C. 112(d).
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Art-Free Subject Matter
It is noted that the sequences of the fusion proteins: (i) a set derived from VHH termed Nb46 comprising the CDR sequences: GYFYYDHYYVA (SEQ ID NO: 2), INGRDSD (Sequence No: 3) and AANPGEAFTVLPPRVERN (SEQ ID NO: 4); and (ii) a set derived from VHH termed Nb38 comprising the CDR sequences: GFTRSMG (SEQ ID NO: 6), INNYNIGSG (SEQ ID NO: 7), and AASPLYLCDNSSWFAAGFAAGSHV (SEQ ID NO: 8).
Nb46 VHH - Amino acid sequence (SEQ ID NO: 1) DSDTYYADSVKGRFTISQDSAKNTVYLQMNSLKPEDTAIYYCAANPGEAFTVLPPRV FRNWGQGTQVTVSS
Nb38 VHH - Amino acid sequence (SEQ ID NO: 5) QVQLQESGGGSVQAGGSLKLSCVASGFTRSMGWARQAPGKEREGVVCINNYNIGSG KWYADSVKGRFTISRDNDKNTVSLQMNSLKPEDTAIYYCAASPLYLCDNSSWFAAG FAAGSHVWGQGTQVTVSS
have all been thoroughly searched and are free of the prior art. However, the instant claims suffer from deficiencies under 35 U.S.C 112(a) written description and enablement issues.
The closest prior art made of record but not relied upon is EP3643726A1 (2020, Ting, Hong hoi, Wong, Chung Lim, Huang, Wenhua) as it teaches similar subject matter relating to the present application (18/848326), however, the VHH sequences and the CDR sequences of 18/848326 (Claims, summary of the invention, pg.2,4,8, line 15) do not match with the sequences cited (SEQ ID No:1 -40; CDR regions of 40 strains of nanobody, detailed description, paragraph 160, pg. 15-20) in the closest prior art (EP3643726A1). Ting, H.H. et. al. teach a VHH chain of anti- HER2 nanobody against HER2 epitope, wherein amino acid sequence of the VHH chain is shown as any one of SEQ ID Nos.: 1-40 (Claims). Ting, H.H. et. al. further teaches a nanobody combating human HER2/ERBB2, the gene sequence encoding the nanobody, a corresponding expression vector, a host cell, a method for producing nanobody, an immunoconjugate of the nanobody and use in diagnosis and treatment of HER2 positive tumor (Abstract).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINJAL JITENDRAKUMAR PANCHOLI whose telephone number is (571)270-7486. The examiner can normally be reached Monday - Thursday 8:30am - 5:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at 571-270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format.
For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/M.J.P./ Examiner, Art Unit 1642
/SAMIRA J JEAN-LOUIS/ Supervisory Patent Examiner, Art Unit 1642